Genetic Analysis AS (XSAT:GEAN) Beginning Cash Position: kr19.78 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:GEAN Genetic Analysis AS XSAT:GEAN
27 GF Score
Price kr0.51
GF Value kr0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Genetic Analysis AS Beginning Cash Position?

Genetic Analysis AS XSAT:GEAN +2.00% 27 Beginning Cash Position is kr19.78 Mil as of Jun. 2026. GuruFocus rates XSAT:GEAN with a GF Score™ of 27/100 and a GF Value™ of kr0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Genetic Analysis AS's Beginning Cash Position for the quarter that ended in Jun. 2026 was kr19.78 Mil.

Genetic Analysis AS's quarterly Beginning Cash Position increased from Dec. 2025 (kr17.63 Mil) to Mar. 2026 (kr24.03 Mil) but then declined from Mar. 2026 (kr24.03 Mil) to Jun. 2026 (kr19.78 Mil).

Genetic Analysis AS's annual Beginning Cash Position declined from Dec. 2023 (kr25.32 Mil) to Dec. 2024 (kr16.29 Mil) and declined from Dec. 2024 (kr16.29 Mil) to Dec. 2025 (kr13.37 Mil).

Genetic Analysis AS Beginning Cash Position Related Terms

Genetic Analysis AS Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Genetic Analysis AS's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetic Analysis AS Beginning Cash Position Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 24.19 46.81 25.32 16.29 13.37

Genetic Analysis AS Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.53 25.09 17.63 24.03 19.78
XSAT:GEAN
27GF Score
Genetic Analysis AS XSAT:GEAN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetic Analysis AS Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of kr19.78 Mil mean?
Genetic Analysis AS (XSAT:GEAN) has a Beginning Cash Position of kr19.78 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Analysis AS and its competitors.
Is Genetic Analysis AS's Beginning Cash Position too high?
Genetic Analysis AS's current Beginning Cash Position is kr19.78 Mil. Overall, Genetic Analysis AS has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's Beginning Cash Position compare to TMO and DHR?
Genetic Analysis AS's Beginning Cash Position of kr19.78 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Diagnostics & Research company?
A good Beginning Cash Position depends on the Medical Diagnostics & Research industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Genetic Analysis AS and its competitors. Genetic Analysis AS's current Beginning Cash Position is kr19.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.37, compared to a current price of kr0.51 — trading 37.8% above its estimated fair value. The current Beginning Cash Position is kr19.78 Mil. Genetic Analysis AS's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current Beginning Cash Position is kr19.78 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?

Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued. The current stock price of kr0.51 is trading 37.8% above its estimated GF Value™ of kr0.37. GuruFocus considers Genetic Analysis AS to be Significantly Overvalued.

Key valuation signals for XSAT:GEAN:

  • Beginning Cash Position: kr19.78 Mil
  • GF Value™: kr0.37 vs. price of kr0.51 (37.8% above fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetic Analysis AS Business Description

Other Exchanges 8V8:Germany
Address Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
27GF Score

Get the complete analysis for XSAT:GEAN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.51
Price
kr0.37
GF Value